Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M O'Malley

Showing results (1-10 of 235) with videos related to

Pageof 24
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
New Therapies for Ovarian CancerDavid M O'Malley
Gynecologic Oncology|October 16, 2012
Here it comes....the role of cost-effective analysisRitu Salani, David M O'Malley
Expert Opinion on Biological Therapy|May 29, 2020
Antibody-drug conjugates for the treatment of ovarian cancerCorinne A Calo, David M O'Malley
Current Oncology Reports|June 14, 2021
Progress in Gynecologic Cancers with Antibody Drug ConjugatesDavid M O'Malley, Corinne A Calo
Expert Opinion on Drug Safety|November 20, 2018
How safe is rucaparib in ovarian cancer?Casey M Cosgrove, David M O'Malley
Gynecology and Pelvic Medicine|May 29, 2026
Is it time to add <i>BRCA1</i> promoter methylation testing in the arsenal of ovarian cancer diagnostic tools?Monica D Levine, Leigha Senter, David M O'Malley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Reply to G.B. HoltAlexi A Wright, Angel Cronin, David M O'Malley
Gynecologic Oncology|August 14, 2015
Highlights from the Society of Gynecologic Oncology 2015 Annual Meeting on Women's CancerCamille C Gunderson, Jeff Boyd, David M O'Malley
Journal of Surgical Oncology|September 20, 2015
The role of robotic surgery in endometrial cancerDavid M O'Malley, Blair Smith, Jeffrey M Fowler
Gynecologic Oncology|February 11, 2023
Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer"David M O'Malley, Jonathan A Ledermann, Robert L Coleman
Pageof 24

Showing results (1-10 of 235) with videos related to

Sort By:
Pageof 24
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
New Therapies for Ovarian CancerDavid M O'Malley
Gynecologic Oncology|October 16, 2012
Here it comes....the role of cost-effective analysisRitu Salani, David M O'Malley
Expert Opinion on Biological Therapy|May 29, 2020
Antibody-drug conjugates for the treatment of ovarian cancerCorinne A Calo, David M O'Malley
Current Oncology Reports|June 14, 2021
Progress in Gynecologic Cancers with Antibody Drug ConjugatesDavid M O'Malley, Corinne A Calo
Expert Opinion on Drug Safety|November 20, 2018
How safe is rucaparib in ovarian cancer?Casey M Cosgrove, David M O'Malley
Gynecology and Pelvic Medicine|May 29, 2026
Is it time to add <i>BRCA1</i> promoter methylation testing in the arsenal of ovarian cancer diagnostic tools?Monica D Levine, Leigha Senter, David M O'Malley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Reply to G.B. HoltAlexi A Wright, Angel Cronin, David M O'Malley
Gynecologic Oncology|August 14, 2015
Highlights from the Society of Gynecologic Oncology 2015 Annual Meeting on Women's CancerCamille C Gunderson, Jeff Boyd, David M O'Malley
Journal of Surgical Oncology|September 20, 2015
The role of robotic surgery in endometrial cancerDavid M O'Malley, Blair Smith, Jeffrey M Fowler
Gynecologic Oncology|February 11, 2023
Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer"David M O'Malley, Jonathan A Ledermann, Robert L Coleman
Pageof 24